Agent Skills
› brycewang-stanford/Awesome-Journal-Skills
› cc-ethics-registration
cc-ethics-registration
GitHub用于组装癌症细胞（Cell Press）稿件的伦理批准和数据可用性声明。涵盖IACUC动物审批、IRB人类样本同意书、生物安全合规及数据/代码归档声明，确保符合期刊规范，不涉及实验设计。
Trigger Scenarios
研究涉及动物、人类样本或危险试剂
需要生成IACUC/IRB/同意书/生物安全声明
需要编写数据和代码可用性声明及获取登录号
临床试验组件可能需要注册信息
Install
npx skills add brycewang-stanford/Awesome-Journal-Skills --skill cc-ethics-registration -g -y
SKILL.md
Frontmatter
{
"name": "cc-ethics-registration",
"description": "Use when assembling ethics approvals and availability statements for a Cancer Cell (Cell Press) manuscript — IACUC animal approval, human-sample IRB\/consent, biosafety, and data\/code deposition statements. It governs compliance declarations; it does not design experiments or write methods detail."
}
Ethics, Approvals & Data Availability (cc-ethics-registration)
When to trigger
- The study uses animals, human samples, or hazardous agents
- You need the IACUC / IRB / consent / biosafety statements
- You need the Data and code availability statement and accessions
- A clinical-translational component may need trial registration
Animal work — IACUC
- State that all animal procedures were approved by the institutional IACUC (or equivalent), with the protocol number and institution.
- Confirm compliance with relevant national/institutional guidelines.
- Pair with ARRIVE-style methods reporting (sample size, randomization, blinding, humane endpoints) handled in
cc-reporting-standards.
Human samples — IRB & consent
- State IRB / ethics committee approval (institution + protocol).
- State that informed consent was obtained (or a documented waiver and its basis).
- Affirm compliance with the Declaration of Helsinki for human-subjects research.
- For patient-identifiable genomic data, note controlled-access deposition (dbGaP/EGA) and any data-use limitations.
- If a clinical trial provided samples/outcomes, give the registration number (e.g., ClinicalTrials.gov) and registry.
Biosafety & other compliance
- Note biosafety level / institutional biosafety approval for pathogens, lentivirus/retrovirus, or hazardous reagents where relevant.
- Recombinant DNA / dual-use considerations if applicable.
- Disclose any field-collected or regulated materials (permits).
Data and code availability (Cell Press standard)
Provide an explicit statement with three components:
- Data — all newly generated datasets deposited and accessions listed (GEO/SRA for sequencing; dbGaP/EGA for controlled human genomics; PRIDE for proteomics; PDB/EMDB for structures; MetaboLights/Workbench for metabolomics). State public availability as of publication date.
- Code — any original/custom code deposited in a citable repository with a DOI (e.g., Zenodo release of a GitHub tag).
- Other — any additional information/reagents available from the lead contact on request.
Accessions must also appear in the Key Resources Table. "Available on request" is not acceptable for the data types above.
Authorship & disclosure (usually adjacent)
- Author contributions (CRediT-style), competing-interests declaration, and funding statement are typically required — confirm current sections on the author page.
Checklist
- IACUC approval stated with protocol # and institution (if animals)
- IRB/ethics approval + informed consent (or waiver) stated (if human samples)
- Declaration of Helsinki compliance affirmed (human subjects)
- Controlled-access deposition noted for patient-identifiable genomics
- Trial registration number given (if a registered trial supplied data)
- Biosafety / hazardous-agent approvals noted where relevant
- Data availability: all accessions listed and in the KRT
- Code deposited with a citable DOI
- Competing interests, funding, and author contributions drafted
Anti-patterns
- "Animal experiments followed guidelines" with no IACUC approval/number
- Human samples used with no IRB/consent statement
- Genomic patient data with no controlled-access plan
- "Data available upon request" for sequencing/proteomics/structures
- Missing or vague competing-interests / funding declarations
- Trial-derived data with no registration number
Ethics pass for Cancer Cell
Use this as a second-pass capability check. First lock the cancer context, mechanism, model system, validation chain, and translational boundary; then test whether the manuscript addresses cancer-biology reviewers who expect mechanistic oncology, translational relevance, and strong multi-modal validation.
- Primary move: Check consent/approval, registration, safety, privacy, data sharing, and disclosure statements before claiming compliance.
- Decision ledger: return
claim / evidence / blocker / next editrows so the next pass can patch the manuscript directly. - Neighbor test: compare against Cell for broader biology, Nature Cancer for oncology breadth, Clinical Cancer Research for clinical translation; if the neighboring outlet has the stronger audience claim, recommend re-routing before polishing.
- Verification floor: before submission-ready advice, re-open
resources/official-source-map.mdfor volatile rules and name the one unresolved fact that could change the recommendation.
Output format
【Animal】IACUC approval + protocol #? Y/N
【Human】IRB + consent + Helsinki? controlled-access if needed? Y/N
【Biosafety】approvals noted where relevant? Y/N
【Trial registration】number given (if applicable)? Y/N
【Data availability】accessions listed + in KRT? Y/N
【Code】DOI deposited? Y/N
【Disclosures】competing interests / funding / contributions? Y/N
【Next step】cc-writing-style or cc-submission
Version History
- 1839142 Current 2026-07-05 12:26
